X

Vous n'êtes pas connecté

Rubriques :

Maroc Maroc - HEALTHTECHZONE.COM - Healthcare Providers - 05/Sep 21:34

Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

Articles similaires

Sorry! Image not available at this time

Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

healthtechzone.com - 05/Sep 21:34

Sorry! Image not available at this time

Travere Therapeutics Announces Full FDA Approval of Filspari (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

drugs.com - 05/Sep 05:09

SAN DIEGO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the U.S. Food and Drug Administration...

Sorry! Image not available at this time

Travere Therapeutics Announces Full FDA Approval of Filspari (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

drugs.com - 05/Sep 05:09

SAN DIEGO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the U.S. Food and Drug Administration...

Sorry! Image not available at this time

Travere Gains 11% on Securing Full FDA Nod for Kidney Disease Drug

zacks.com - 09/Sep 15:58

The approval expands the label of TVTX's Filspari in IgAN indication. However, the label also comes with a boxed warning for liver problems and...

Sorry! Image not available at this time

Travere Gains 11% on Securing Full FDA Nod for Kidney Disease Drug

zacks.com - 09/Sep 15:58

The approval expands the label of TVTX's Filspari in IgAN indication. However, the label also comes with a boxed warning for liver problems and...

Sorry! Image not available at this time

FILSPARI (sparsentan) tablet, film coated [Travere Therapeutics, Inc.]

nlm.nih.gov - 10/Sep 04:00

Updated Date: Tue, 10 Sep 2024 00:00:00 EDT

Sorry! Image not available at this time

FILSPARI (sparsentan) tablet, film coated [Travere Therapeutics, Inc.]

nlm.nih.gov - 10/Sep 04:00

Updated Date: Tue, 10 Sep 2024 00:00:00 EDT

Sorry! Image not available at this time

Idiopathic Membranous Nephropathy Treatment Market Size in the 7MM is expected to reach ~USD 1,000 million by 2034

mountaintoday.in - 17/Sep 18:21

Idiopathic Membranous Nephropathy Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in...

Sorry! Image not available at this time

Denali Plans to File for Accelerated Approval of Hunter Syndrome Drug

zacks.com - 04/Sep 15:37

DNLI's recent meeting with the FDA was successful and provides the path to file for accelerated approval of tividenofusp alfa for the treatment of MPS...

Sorry! Image not available at this time

Denali Plans to File for Accelerated Approval of Hunter Syndrome Drug

zacks.com - 04/Sep 15:37

DNLI's recent meeting with the FDA was successful and provides the path to file for accelerated approval of tividenofusp alfa for the treatment of MPS...

Les derniers communiqués